Article Details

Despite FTC's harsh words for biopharma M&A, Bristol Myers CEO Caforio still enthusiastic about ...

Retrieved on: 2021-05-03 15:45:00

Tags for this article:

Click the tags to see associated articles and topics

Despite FTC's harsh words for biopharma M&A, Bristol Myers CEO Caforio still enthusiastic about .... View article details on hiswai:

Excerpt

Morgan Stanley analysts downgraded BMS' stock from overweight to equal weight last week, noting that they're “uninspired” by the company's drugs ...

Article found on: www.fiercepharma.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo